Safety and Efficacy of Adjunct Therapies in Adults With Type 1 Diabetes: Multicenter, Registry Study
ConditionType 1 Diabetes
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorIndiana University
About this trial
This will be a multicenter registry-based study to evaluate safety and efficacy of GLP-1RA and SGLTi therapies in adjunct to insulin in adults with type 1 diabetes (T1D) over 1 year. This study will enroll participants who have been prescribed adjunct therapy as part of usual care.
Eligibility criteria
Qualifiers
Adults ≥18 years of age
Clinical diagnosis of T1D
GLP-1RA or SGLTi (SGLT-1 and SGLT-2 inhibitors) drug prescribed by their provider for any indication as part of usual care with use for no more than 1 week
Use of CGM and availability of CGM data for 1 month prior to enrollment and expected to be available throughout the study
Disqualifiers
No exclusion criteria other than those not meeting inclusion criteria above
Trial design
Treatments tested in this trial
- Not listed
Trial groups
No trial groups listed
Locations
7California
Hoag Memorial Hospital92663, Newport Beach United States
Georgia
Emory University30303, Atlanta United States
Illinois
Northwestern University60611, Chicago United States
Maine
Maine Health Research Institute04102, Portland United States
Sponsors and collaborators
Indiana University
Lead sponsor
Jaeb Center for Health Research
Collaborator
Source ClinicalTrials.gov